Clinical trial
An Open Label, Phase I, Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Volasertib in Combination With Decitabine in Patients >= 65 Years With Acute Myeloid Leukemia
NCT02003573 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open Label, Phase I, Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Volasertib in Combination With Decitabine in Patients >= 65 Years With Acute Myeloid Leukemia
- Lead sponsor
- Boehringer Ingelheim
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- January 29, 2014
- Completion date
- May 15, 2016
- Enrollment
- 13 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.